A detailed history of Advisor Group Holdings, Inc. transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 103,192 shares of IBRX stock, worth $315,767. This represents 0.0% of its overall portfolio holdings.

Number of Shares
103,192
Previous 74,854 37.86%
Holding current value
$315,767
Previous $473,000 19.24%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.32 - $6.7 $94,082 - $189,864
28,338 Added 37.86%
103,192 $382,000
Q2 2024

Aug 13, 2024

BUY
$4.82 - $9.15 $152,779 - $290,027
31,697 Added 73.45%
74,854 $473,000
Q1 2024

May 10, 2024

BUY
$3.23 - $6.17 $40,727 - $77,797
12,609 Added 41.28%
43,157 $231,000
Q4 2023

Feb 12, 2024

BUY
$1.25 - $5.21 $2,303 - $9,602
1,843 Added 6.42%
30,548 $153,000
Q3 2023

Nov 13, 2023

BUY
$1.29 - $3.1 $20,416 - $49,063
15,827 Added 122.9%
28,705 $48,000
Q2 2023

Aug 10, 2023

SELL
$1.53 - $6.41 $16,271 - $68,170
-10,635 Reduced 45.23%
12,878 $35,000
Q1 2023

May 12, 2023

SELL
$1.35 - $4.78 $3,450 - $12,217
-2,556 Reduced 9.8%
23,513 $42,000
Q4 2022

Feb 10, 2023

SELL
$4.35 - $6.77 $40,076 - $62,372
-9,213 Reduced 26.11%
26,069 $132,000
Q3 2022

Nov 14, 2022

BUY
$3.65 - $6.43 $10,084 - $17,766
2,763 Added 8.5%
35,282 $176,000
Q2 2022

Aug 10, 2022

BUY
$2.68 - $6.14 $53,943 - $123,585
20,128 Added 162.44%
32,519 $122,000
Q1 2022

May 04, 2022

SELL
$5.05 - $7.53 $98,121 - $146,307
-19,430 Reduced 61.06%
12,391 $69,000
Q3 2021

Nov 05, 2021

BUY
$9.17 - $14.24 $172,240 - $267,469
18,783 Added 144.06%
31,821 $309,000
Q2 2021

Aug 02, 2021

BUY
$13.41 - $22.4 $117,578 - $196,403
8,768 Added 205.34%
13,038 $186,000
Q1 2021

May 13, 2021

BUY
$12.83 - $42.25 $54,784 - $180,407
4,270 New
4,270 $102,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.22B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.